News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
Avexxin Completes Phase I/IIA Study In Psoriasis And Achieves Proof-Of-Concept In Man With Its Compound AVX001 In A Topical Formulation 7/2/2015
Evotec AG (EVTG.F), Roche (RHHBY)'s Alzheimer's Hopeful Fails Another Trial 7/2/2015
Teva (TEVA) And Xenon Pharmaceuticals Inc. Provide Update On TV-45070 Phase IIb Study In Osteoarthritis Pain 7/1/2015
Replicel Life Sciences Enrolls First Participant In Phase 1/2 Clinical Trial Of RCT-01 For Chronic Achilles Tendinosis 6/30/2015
Pharma Two B Ltd. Announces Positive Results In Its Phase Ilb Pivotal Clinical Study Of P2B001 For The Treatment Of Early Stage Parkinson's Disease 6/30/2015
BioBlast Pharma (ORPN) Receives Orphan Drug Designation From The European Commission (EC) For Cabaletta For The Treatment Of Spinocerebellar Ataxia (SCA) 6/29/2015
Aquinox (AQXP)’s Bladder Pain Drug Fails to Meet Statistical Endpoint in Phase II Trial 6/25/2015
Transition Therapeutics Inc. (TTH.TO) Announces Results Of Clinical Study Of ELND005 In Agitation And Aggression In Patients With Alzheimer's Disease 6/24/2015
Alcobra (ADHD)’s Fragile X Syndrome Drug Fails During Mid-Stage Trial 6/24/2015
ObsEva Announces Recruitment Of The First Patient In TERM Phase 2 Study 6/23/2015
Vaxil BioTherapeutics's Lead Product Immucin Has Been Granted An Orphan Drug Designation By The FDA For The Treatment Of Multiple Myeloma 6/22/2015
Galapagos (GLPG.BR) Completes Recruitment For ORIGIN Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 6/18/2015
BiondVax Pharmaceuticals Announces FDA Acceptance Of IND Application For Its Investigational Universal Flu Vaccine 6/17/2015
Akaal Pharma Receives Approval To Initiate Phase II Clinical Trial For The Topical Treatment Of Psoriasis 6/16/2015
Teva (TEVA) Advances Pipeline Of Movement Disorder Assets With Announcement Of Positive Top-Line Data From The First Pivotal Study Of Investigational Treatment For Patients With Tardive Dyskinesia 6/16/2015
CTI BioPharma Release: Tosedostat In Combination With Low Dose Cytarabine Achieves Primary Endpoint In Phase 2 Study In Elderly Patients With AML 6/15/2015
Amarillo Biosciences (AMAR) Announces Presentation Of Eltoprazine Phase I/IIa Clinical Data At The 19th International Congress Of Parkinson's Disease And Movement Disorders 6/15/2015
BioLineRx Ltd. Presents Positive Safety And Efficacy Results For Novel Stem-Cell Mobilization Treatment At European Hematology Association Conference 6/15/2015
Celgene (CELG) Release: Results From Analyses Of Revlimid MCL-002 (SPRINT) Study Presented At European Hematology Association 6/15/2015
NeuroDerm (NDRM) Announces Start Of A Pharmacokinetic, Head-To-Head Comparison Study Of ND0612H And Duodopa 6/11/2015
Verona Pharma (VRP.L) Release: RPL554 Phase 2a Trial Started; Headline Data Expected Q1 2016 6/11/2015
ALK-Abello A/S's Partner, MSD, Publishes Phase II Data On House Dust Mite SLIT-Tablet In Leading Allergy Journal Journal 6/10/2015
Postive Trial Results Of Mesoblast (MSB.AX) Cell Therapy In Patients With Diabetes And Advanced Chronic Kidney Disease 6/9/2015
RedHill Biopharma Ltd. (RDHL) Announces Completion Of Patient Enrollment In The Phase IIa Study Of RHB-104 For Multiple Sclerosis 6/9/2015
Nuvo Research Inc. (NRI.TO) Receives Health Canada Approval To Conduct New WF1 Phase 2 Trial 6/8/2015
Aimmune's Peanut Allergy Drug Desensitizes Patients in Phase II Studyl 6/8/2015
Aimmune Therapeutics Announces Positive Phase 2 Study Results Of AR101 For The Treatment Of Peanut Allergy 6/8/2015
Poxel’s Novel Anti-diabetic Agent Imeglimin Meets Glycemic Endpoints in Phase 2b Dose-Ranging Trial 6/8/2015
Hanmi Pharma: Efpeglenatide (GLP-1 Analog), The Promising Potential For Anti-Diabetes/Anti-Obesity Treatment As Once Weekly Up To Once Monthly 6/8/2015
Amarantus BioSciences, Inc. Opens First Clinical Trial Site And Commences Patient Enrollment For Lead Product Candidate Eltoprazine's Phase IIb Study In Parkinson's Disease Levodopa-Induced Dyskinesia 6/5/2015
Cellular Biomedicine Group (CBMG) Announces Publication Of Human Adipose-Derived Progenitor Cells To Treat Knee Osteoarthritis 6/5/2015
Dezima Pharma's CETP Inhibitor, TA-8995, Phase IIb (TULIP) Study Results Published In The Lancet 6/3/2015
ASCO15: Ascentia Pharma Inc. Release: New Enzalutamide Data In Triple-negative Breast Cancer Presented At The 2015 American Society Of Clinical Oncology Annual Meeting 6/2/2015
New Data On Lixisenatide (Lyxumia) Including ELIXA Results On Lixilan, And On Novel Zealand Pharma  (ZEAL.CO) Peptide Therapeutics, To Be Presented At The American Diabetes Association's 75th Scientific Sessions 6/2/2015
ASCO15: VBL Therapeutics (VBLX) Reports Updated Interim Results From Phase II Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 6/1/2015
PRANA Biotechnology (PRAN) Release: European Commission (EC) Approves PBT2 Orphan Designation For Huntington’s Disease 6/1/2015
Symphogen A/S’s Antibody Mixtures Highlighted In Three Peer-Reviewed Journals 5/28/2015
Novartis AG (NVS) to Show Off New Data on 21 Meds and 11 Investigational Compounds at Major Conferences 5/27/2015
Synageva BioPharma (GEVA) Submits Kanuma (Sebelipase Alfa) Application For LAL Deficiency In Japan 5/27/2015
Gordagen Commences Clinical Trial Program For Evidence-Based Nutraceuticals 5/27/2015
Prima Biomed (PRR.AX) Release: CVac Shows Clear Trend For Overall Survival Benefit In Second Remission Ovarian Cancer In Phase II Study 5/26/2015
Onxeo Announces Final Data From Completed Phase II Trial Of Validive For The Prevention Of Severe Oral Mucositis In Head And Neck Cancer Patients 5/26/2015
Amarantus BioSciences, Inc. Enters Into CRO Agreement With Chiltern International Ltd. To Commence Phase IIb Clinical Development Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 5/21/2015
Kamada Ltd. (KMDA) Reports Updated Data From European Phase II/III Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 5/20/2015
Targovax Announces Presentation Of Data From The Ongoing Phase I/II Clinical Study Of The RAS-Specific Therapeutic Cancer Vaccine TG01 In Resected Pancreatic Cancer At ASCO 2015 In Chicago 5/19/2015
Prima Biomed (PRR.AX) Release: CVAC Shows Overall Survival Benefit In Second Remission Ovarian Cancer In Phase II Study 5/19/2015
Mesoblast (MSB.AX) Release: Diabetic Nephropathy Trial Results Selected For Late-Breaking Presentation At American Diabetes Association Annual Meeting 5/18/2015
Theravance Biopharma Presents Positive Phase 2 Study Data On Velusetrag (TD-5108) For Treatment Of Gastroparesis In "Poster Of Distinction" At Digestive Disease Week (DDW) 2015 5/18/2015
D-Pharm Ltd. Receives Final Report For Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 5/14/2015
Immodulon Therapeutics Release: New Data From IMAGE 1 Show Improved Survival In Metastatic Pancreatic Cancer In Patients Receiving IMM-101 5/14/2015
Generex Biotechnology Corporation (GNBT) Provides Data Update From AE37 Phase II Breast Cancer Trial One Year Post Completion Of Enrollment 5/14/2015
Teva (TEVA) Presents Further Data From Phase IIb With TEV-48125 In Chronic Migraine At The International Headache Society Congress (IHC): Efficacy And Safety Results At All Doses And Endpoints Present Robust Case For Progression To Phase III 5/14/2015
FDA Lifts Clinical Hold on NeuroDerm (NDRM)'s Lead Parkinson's Candidates 5/11/2015
Zafgen (ZFGN) Presents Positive Safety And Efficacy Data From Phase II Trial Of Beloranib In Severe Obesity And Proof Of Concept Trial In Prader-Willi Syndrome At ECO 2015 5/8/2015
MSI Methylation Sciences, Inc. (MSI) Completes Recruitment Of Phase 2 Trial For Its Novel Treatment STRADA For Major Depressive Disorder (MDD) 5/7/2015
(MSI) Completes Recruitment Of Phase 2 Trial For Its Novel Treatment STRADA For Major Depressive Disorder (MDD) 5/7/2015
Onxeo : Oral Presentation Of Phase II Trial Results Of Validive At The MASCC/ISOO International Symposium 5/6/2015
BioLineRx Ltd. Initiates Expansion Stage Of Phase 2 Clinical Trial For Novel Treatment For Acute Myeloid Leukemia 5/4/2015
Generon (Shanghai) Corporation Ltd. Received FDA Clearance To Initiate Phase IIa Study With F-652, A First-In-Class Biologic, To Treat Patients With Acute GvHD 5/4/2015
Can-Fite BioPharma (CFBI) Subsidiary, OphthaliX, Signs Term Sheet To Acquire Improved Vision Systems Ltd. 5/4/2015
Shanghai Generon To Start US Trial Of GvHD Biologic Drug 5/4/2015
TaiGen Biotechnology Announces Initiation of Burixafor Chemosensitization Clinical Trial In Acute Myeloid Leukemia In China 4/30/2015
Amarantus BioSciences, Inc. Granted European Union Orphan Drug Designation For MANF For The Treatment Of Retinitis Pigmentosa 4/29/2015
PRANA Biotechnology (PRAN) Release: PBT2 Recommended For Orphan Designation In Europe 4/28/2015
Eiger Biopharma Announces Interim Results Of Lonafarnib In Combination With Ritonavir Or Pegylated Interferon In Patients Infected With Hepatitis Delta Virus (HDV) 4/27/2015
Imperial Innovations Release: Autifony Therapeutics Recruits First Patient Into Phase IIa Trial For Age Related Hearing Loss 4/27/2015
NeuroVive: FIrst Patient Enrolled In Clinical Phase II Study For Kidney Protection During Heart Surgery 4/27/2015
Gilead (GILD) Announces Results From Studies Evaluating Sofosbuvir-Based Regimens In Chronic Hepatitis C Patients With Genotypes 2-5 4/27/2015
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1450 In Staphylococcal Skin Infections 4/23/2015
Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome 4/23/2015
Teva (TEVA) And Active Biotech AB (BTPC) Announce First Patient Enrolled In Phase II Study Evaluating Laquinimod For Primary Progressive MS 4/23/2015
Roche (RHHBY) Still Bullish on Alzheimer’s Research After Biogen (BIIB)’s Successful Clinical Trial 4/22/2015
Pharmaleads Announces The Inclusion Of The First Patient In Phase IIa Study Of Oral PL37 For Pain In Diabetic Neuropathy 4/22/2015
NeuroVive: Clinical Phase II Study With Neurostat For Traumatic Brain Injury Passes Safety Evaluation 4/21/2015
Pluristem Therapeutics (PSTI)'s Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan 4/20/2015
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015
Biothera Immunotherapy Combination Results In Tumor Reduction During Maintenance Phase Of Non-Small Cell Lung Cancer Study 4/15/2015
Pharmalink AB Phase II Trial Of Nefecon Halted Early 4/14/2015
Mechanism Of Action Of ABIVAX's First-in-class Anti-HIV Drug Published Today In Peer-Reviewed Journal Retrovirology 4/13/2015
Admedus Herpes Phase II – First Dosing To Commence 4/10/2015
Onxeo Release: Belinostat Phase I/II Results In Soft Tissue Sarcoma To Be Presented At The 2015 Annual ASCO Meeting 4/9/2015
Rhythm Initiates Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/8/2015
Alkermes (ALKS) Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 4/6/2015
AstraZeneca PLC (AZN)'s Failed Cancer Drug Finds New Life in Alzheimer’s Treatment 4/3/2015
Clementia Advances Phase 2 Clinical Trial Of Palovarotene In Fibrodysplasia Ossificans Progressiva Based On Recommendations From Data Monitoring Committee (DMC) 4/2/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
NeuroDerm Ltd. (NDRM) To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy of Neurology 4/1/2015
Hutchison Medipharma's Cancer Drug Meets Endpoint In Phase II Trial 4/1/2015
RedHill Biopharma Ltd. (RDHL) Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech 3/31/2015
Innate Pharma (IPH.PA ) : DSMB Recommends Continuation Of Effikir Trial With Two Arms 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
NIH Release: Ebola Test Vaccines Appear Safe In Phase 2 Liberian Clinical Trial 3/27/2015
GENFIT (ALGFT) Announces Topline Results From The Golden-505 Trial In Nash 3/26/2015
Apceth GmbH Initiates Phase II Clinical Trial For Pioneering Engineered Cell Therapy To Treat Gastrointestinal Cancer 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
VBL Therapeutics (VBLX) Reports Interim Topline Results From Phase 2 Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Interim Results From Phase IIb Clinical Trial For Knee Osteoarthritis Stem Cell Rejoin Therapy 3/25/2015
Mologen AG (MOLGF.PK): Start Of Pivotal Study For Cancer Immunotherapy MGN1703 Influences 2014 Annual Result 3/25/2015
Pluristem Therapeutics (PSTI) Announces Key Strategic Objectives For Development Of PLX-R18 In Hematopoietic Indications 3/24/2015
MediGene AG (MDGEF.PK) Starts Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015 3/23/2015
Teva (TEVA)'s TEV-48125 Meets Primary And Secondary Endpoints In Episodic Migraine Study, Demonstrating Treatment Concept After A Single Dose 3/23/2015
Bone Therapeutics Treats First Patients In ALLOB Phase IIA Spinal Fusion Trial 3/23/2015
Dilaforette Receives Orphan Drug Designation In The U.S. For Sevuparin In Sickle-Cell Disease 3/20/2015
Dignity Sciences Presents Late-Breaking News Abstract On DS107 At American Academy of Dermatology Annual Meeting 3/20/2015
BioInvent (BOVNF) Confirms Clinical Strategy For BI-505 And Plans To Conduct Phase IIa Trial In Multiple Myeloma Post-Stem Cell Transplant Patients In The U.S. 3/19/2015
Hemostemix Expands Clinical Trial For Critical Limb Ischemia (CLI) To Four Sites In South Africa, Treats First South African Participant 3/19/2015
Creabilis' CT327 Phase 2b Data Published In Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 3/19/2015
Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug 3/18/2015
Imperial Innovations' Cell Medica Granted Orphan Drug Designation For Novel Cellular Therapy And Treats First Lymphoma Patient In CITADEL Phase II Trial 3/18/2015
Ablynx (ABLYF) Initiates The First Of Two Phase IIb Ra Studies With Its Anti-Il-6R Nanobody, Partnered With AbbVie (ABBV) 3/17/2015
NovImmune SA Release: New Drug Begins Testing As First-Line Treatment For Fatal Childhood Disease 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
AB Science (AB.PA) : Positive Phase II Clinical Study Data Of Masitinib In Triple Negative Breast Cancer 3/13/2015
Theravance Biopharma Announces Initiation Of Phase 2b Study Of Velusetrag (TD-5108) For The Treatment Of Gastroparesis 3/13/2015
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Elafin Combined With Cyclosporine Promises To Overcome Limitations Of Cyclosporine For Preventing Irreversible Damage To Transplanted Organs 3/12/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
Herantis Pharma's Phase 2 Dry Eye Study Recruitment Completed Ahead Of Schedule 3/11/2015
Galmed Pharmaceuticals Announces The Beginning Of Enrollment In Its Phase IIb ARREST Trial For The Treatment Of NASH, As Well As The Expansion Of The Study To The United States 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Probiodrug AG Announces Enrolment Of First Patient In Phase 2 Study Of Novel Treatment For Alzheimer’s Disease 3/9/2015
Hua Medicine Files To Start U.S. Trial Of Novel Diabetes Drug 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
Hemostemix Expands Clinical Trial For Treating Critical Limb Ischemia To The Peter Munk Cardiac Centre At Toronto General Hospital 3/6/2015
ViroMed Co., Ltd. dba VM BioPharma: A Phase 2 Study Done At Northwestern Hospital Shows Potential Relief For Diabetics With Painful Condition 3/6/2015
Pharma Two B Completes Enrollment In Phase IIb Study Of P2B001 For Parkinson's Disease 3/4/2015
ORYX' Therapeutic Vaccine Micoryx Successfully Completes Phase 1/2a Trial To Treat MSH-H Colorectal Cancer 3/4/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Alizé Pharma Launches Phase 2 Clinical Trial Of AZP-531 In Prader-Willi Syndrome 3/2/2015
BioLineRx Ltd. Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment 3/2/2015
Opsona Therapeutics Ltd. Commences Part B Of Phase II Study Of Blocking Toll-Like Receptor 2 In Extended Criteria Donor Renal Transplant Recipients At High Risk Of Early Graft Dysfunction 3/2/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Phosphate Therapeutics Announces Completion Of Subject Recruitment Into The PEACH Pivotal Phase 2 Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 2/26/2015
ISA Pharmaceuticals Announces Start Of First Phase 1/2 Clinical Trial Of Its SLP®-AMPLIVANT® Conjugates 2/26/2015
Dilafor Announces Positive Results From A Multi Dosing Safety And Pharmacokinetic Clinical Study 2/25/2015
Teva Pharmaceutical Industries (TEVA) Announces Positive Results For TEV-48125 In Phase IIb Chronic Migraine Study Meeting Primary And Secondary Endpoints 2/24/2015
Emisphere Technologies, Inc. (EMIS) Highlights Positive Phase 2 Og217sc Data From Eligen Licensee Novo Nordisk A/S (NVO) 2/23/2015
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015
Galapagos NV (GLPG.BR) Reports That The Last Patient In Darwin 1 Has Completed 12 Weeks Of Treatment 2/23/2015
Anergis Presents Sustained Efficacy Data From Its Allert Phase 2b Trial At The AAAAI Annual Meeting 2/23/2015
Shares Surge as Novo Nordisk A/S (NVO) Shows Off Positive Trial Data for Oral Insulin 2/23/2015
Novo Nordisk A/S (NVO) Announces Positive Results For Phase 2 Trial With Oral Semaglutide In People With Type 2 Diabetes 2/20/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase 2 Colorectal Cancer Study 2/18/2015
BioTie Therapies Corp.: BTT1023 Receives Positive Opinion For Orphan Drug Designation From COMP 2/17/2015
VBL Therapeutics (VBLX) Reports Topline Results From Phase 2 Studies Of VB-201 In Psoriasis And Ulcerative Colitis 2/17/2015
Protalix Biotherapeutics, Inc. (PLX) Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium 2/12/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
Amarantus BioSciences, Inc. Announces Publication In BRAIN Of Eltoprazine Phase 2a Clinical Study For Treating Parkinson's Disease Levodopa-Induced Dyskinesia 2/10/2015
Advanced Inhalation Therapies Receives Orphan Drug Designation Of Its Proprietary High Dose Formulation Of Nitric Oxide For Adjunctive Treatment Of Cystic Fibrosis 2/9/2015
Helsinn Healthcare SA And Zealand Pharma  (ZEAL.CO) Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Zealand Pharma  (ZEAL.CO) And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Adocia Reports Positive Results From Phase 2a Clinical Study Of Fast-Acting Insulin, HinsBet 2/5/2015
Qu Biologics Enrolls First Two Participants In Phase 2a Clinical Trial For Lung Cancer 2/4/2015
AB Science (AB.PA): Positive Phase 2 Clinical Study Data Of Masitinib In Second-Line Metastatic Stomach Cancer 2/3/2015
BrainStorm Cell Therapeutics Inc. Announces Positive DSMB Recommendation In Ongoing Phase 2 Trial With NurOwn™ In ALS 2/3/2015
Immuron Release: Patient Recruitment Commenced For Phase 2 NASH Trial 2/3/2015
Genmab A/S (GEN.CO) Announces Preliminary Results In Phase 2 Study Of Daratumumab In Double Refractory Multiple Myeloma 2/3/2015
Treatment Of The First HIV Positive Patient In ABIVAX's Phase 2a Clinical Trial With ABX464 2/2/2015
Biomay AG Reports Positive Phase 2b Data With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 1/28/2015
Pivotal Therapeutics Inc. Receives Final Approval For Phase 2a Clinical Trial With PVT-100 1/27/2015
Genticel To Continue Per Protocol Its Phase 2 Clinical Study With Procervix After 2nd Review By The DSMB 1/26/2015
GlaxoSmithKline (GSK)'s Long-Awaited Ebola Vaccine Due to Arrive in Liberia 1/26/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
AM-Pharma Starts Adaptive Phase 2 Trial Of Recap In Acute Kidney Injury 1/20/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015
Amarantus BioSciences, Inc. Announces Positive Data From 140 Subject LP-002 Clinical Study Of Lympro Test® Confirming Statistically Significant Markers For Alzheimer's 1/15/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015
Clementia Opens Clinical Trial Site In Europe For Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/9/2015
Bio Blast Provides Update On Clinical Trial Of Cabaletta™ For Occulopharyngeal Muscular Dystrophy (OPMD) 1/8/2015
GW Pharmaceuticals (GWPH) Provides Update On Epidiolex® Program In Treatment Resistant Childhood Epilepsies 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Galapagos Starts Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 1/8/2015
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 1/8/2015
Herantis Pharma Has Initiated Phase 2 Study With Cis-UCA Eye Drops In Patients With Dry Eye Syndrome, Results Expected In Q3/2015 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Otic Pharma Announces Positive Results From A Phase 2 Trial Of Foamotic Externa, Once-A-Day, Single Antibiotic, Steroid Free Product For Acute Otitis Externa (AOE) 1/7/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
BrainStorm Cell Therapeutics Inc. Announces Final Analysis Of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit From NurOwn™ 1/5/2015
NeuroDerm Ltd. (NDRM) Shares Double as Parkinson's Drug Shows Promise in Phase 2 Study 1/2/2015
NeuroDerm Ltd. (NDRM) Announces Topline Results Of Phase 2a Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease 12/31/2014
NeuroLifeSciences Release: Redefining ADHD: A New Approach & A Shift Of Paradigm In ADHD Therapeutics 12/23/2014
BioTie Therapies Corp. Announces Start Of Syn120 Phase 2a Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 12/23/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/22/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014



//-->